Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HSBC "warnings" and GBP potentially dropping 20% is what's causing this fuss.
Had to sell under the bid. Not too many buyers...
Taking more off here.
Bankruptcy not too far away..
Holding up well thus far...
I wouldn't say for years, but I don't think $50 will hit this year unless towards the fall when the Labor Day numbers hit. Maybe over summer if travel is booming and oil is up. I have $48 the top end of this range.
I'm all out myself, missed the rest of this major run.
Thinking of doing the same. Moved my stop up to $6.20
I'm a trader of this myself. But yes, lots of upside with this near all time lows..
Awesome man. Beat me to an exit. I was banking on another leg up. Have a stop at 6.02..
RIP $FIT
Should be good to trade up and down
Wonder if a down market morning will weigh on this?
Eagle Pharmaceuticals Receives Sixth Patent for Bendamustine
Source: Business Wire
-Six Orange Book Listed Patents Running from 2026-2033-
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) (“Eagle” or the “Company”) today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 9,265,831, which pertains to liquid bendamustine hydrochloride (HCl) formulations. The patent issued today expires on January 28, 2031. This new patent, along with five previously issued Patents (Nos. 8,609,707, 8,791,270*PED, 9,000,021, 9,034,908, and 9,144,568), further expands and protects Eagle’s bendamustine HCI intellectual property estate. This grant brings the total number of Orange Book listed patents to six, with this latest patent to be included shortly.
“Eagle continues to strengthen its bendamustine patent portfolio with now six Orange Book listed patents running from 2026-2033 and several more pending. The issuance of this new patent supports the long-term earnings potential of the bendamustine franchise products and further protects its longevity. Given the nature of our patent portfolio, the Company believes that it will be very difficult for any ANDA filers to design around these patents,” said Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals.
Under a February 2015 exclusive license agreement for BENDEKA™ (bendamustine hydrochloride) Injection, Teva Pharmaceuticals is responsible for all U.S. commercial activities for the product including promotion and distribution.
The following table lists the patents for liquid bendamustine hydrochloride (HCl) formulations:
U.S. Patent No. Patent Expiration
8,609,707 8/11/2031
8,791,270*PED (owned by Teva Pharmaceutical
Industries Ltd.)
7/12/2026
9,000,021 3/15/2033
9,034,908 3/15/2033
9,144,568 3/15/2033
9,265,831 1/28/2031
About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.
Forward-Looking Statements
This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and other securities laws. Forward-looking statements are statements that are not historical facts. Words such as “will,” “may,” “intends,” “anticipate(s),” “plan,” “enables,” “potentially,” “entitles,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding future events including, but not limited to: difficulties or delays in manufacturing; the enforceability or defense of intellectual property rights against third parties; the success of Eagle’s commercial relationship with Teva and the companies’ ability to successfully work together; the availability and pricing of third party sourced products and materials, and products licensed to third-parties for promotion and distribution; successful compliance with FDA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; and other factors that are discussed in Eagle’s Annual Report on Form 10-K for the year ended September 30, 2014, and its other filings with the U.S. Securities and Exchange Commission. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond Eagle’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks include, but are not limited to risks described in Eagle’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160223006008/en/
Investor Relations for Eagle Pharmaceuticals, Inc.:
In-Site Communications, Inc.
Lisa M. Wilson, 212-452-2793
lwilson@insitecony.com
Second Sight to Announce Five-Year Data from Argus II Clinical Trial Program
Source: Business Wire
Study Results Will Be Presented at 39th Annual Macula Society Meeting
Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, announced it will unveil five-year outcomes associated with the Argus® II Retinal Prosthesis System ("Argus II") during the 39th Annual Macula Society Meeting, being held February 24-27, 2016, at Eden Roc Miami Beach. James Handa, MD, the Robert Bond Welch Professor of Ophthalmology at the Johns Hopkins University Wilmer Eye Institute, will present the data for the first time during a session on Inherited Retinal Degeneration on Wednesday, February 24th at 6:12 p.m. Eastern Time.
Dr. Handa will present long-term results from an ongoing clinical trial (NCT00407602) assessing 30 individuals from 10 clinical centers blinded (i.e., with bare light perception or worse) from Retinitis Pigmentosa (RP) or similar disorders who were implanted with the Argus II. The data will represent over 200 cumulative patient-years of clinical trial follow-up and will demonstrate the ability for the retinal prosthesis to improve visual function over an extended duration.
“The release of this data represents a milestone in the fight against blindness, given the long-term benefits of the Argus II in restoring some useful vision to individuals blinded by RP. The extended follow-up data clearly demonstrate the utility of the Argus II system, and we have gained considerable knowledge about how best to utilize the device through this trial,” said Dr. Handa.
“We are excited about what this long-term follow up represents, both for patients and for our continued development efforts,” said Dr. Robert Greenberg, Chairman of Second Sight. “These data are compelling in demonstrating the validity of our approach and the reliability of our implants.”
One- and three-year data from the trial were previously published in the peer-reviewed journal Ophthalmology. For the study, three types of visual function tests were performed using computer-run assessments: square localization (i.e. object detection), direction of motion (i.e. motion detection) and discrimination of oriented gratings (i.e. visual acuity). Two types of real-world orientation and mobility (O&M) tests were also performed: a test where patients were asked to locate and touch a door, and a test where patients were asked to follow a white line on the floor. The Functional Low-Vision Observer Rated Assessment (FLORA), a multi-part instrument that was developed specifically for use in patients implanted with a retinal prosthesis who suffer from profound loss of vision or blindness, was used to assess the functional visual abilities of patients and how they use the Argus II to complete a series of common activities of daily living. Before the development of the FLORA, there were no accepted, standardized assessments of functional vision or quality of life that could be used to assess the kind of vision that is restored by a retinal prosthesis. Common assessment tools of functional vision that are available such as the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) or the Massof Activity Inventory have only a few items that can be completed by those with ultra-low vision, with the majority of test items requiring higher levels of spatial vision (ability to read, recognize faces, identify colors).
Earlier results from this trial were used to gain approval of the Argus II by the FDA in addition to CE Mark in Europe. The Argus II System is the first and only retinal implant to have both approvals. Although there are several research efforts in retinal prostheses worldwide, none has demonstrated the same level of reliability and efficacy as the Argus II did in a multi-centered, long-term, controlled clinical trial involving 30 subjects. Today over 180 patients have been treated with the Argus II.
Current research efforts by Second Sight include a feasibility study of the Argus II for individuals with Dry Age-Related Macular Degeneration; hardware and software upgrades for existing and future Argus II patients; and the development of a prosthesis for the primary visual cortex, the Orion™ I Visual Cortical Prosthesis, suitable for patients with other forms of blindness.
About the Argus® II Retinal Prosthesis System
Second Sight's Argus II System provides electrical stimulation that bypasses the defunct retinal cells and stimulates remaining viable cells inducing visual perception in individuals with severe to profound Retinitis Pigmentosa (RP). The Argus II works by converting images captured by a miniature video camera mounted on the patient's glasses into a series of small electrical pulses, which are transmitted wirelessly to an array of electrodes implanted on the surface of the retina. These pulses are intended to stimulate the retina's remaining cells, resulting in the perception of patterns of light in the brain. The patient then learns to interpret these visual patterns, thereby regaining some visual function. The system is controlled by software and is upgradeable, which may provide improved performance as new algorithms are developed and tested. The Argus II is the first artificial retina to receive widespread approval, and is offered at approved centers in Austria, Canada, France, Germany, Italy, Netherlands, Saudi Arabia, Spain, Switzerland, Turkey, United Kingdom and the United States.
About Second Sight
Second Sight's mission is to develop, manufacture and market innovative implantable visual prosthetics to enable blind individuals to achieve greater independence. Second Sight has developed, and manufactures, the Argus® II Retinal Prosthesis intended to provide some useful vision to individuals with outer-retinal degenerations such as Retinitis Pigmentosa (RP). Second Sight is also developing the Orion™ I Visual Cortical Prosthesis to restore some vision to individuals who are blind due to causes other than those currently treated by Argus II or other therapies. U.S. Headquarters are in Sylmar, CA, and European Headquarters are in Lausanne, Switzerland. For more information, visit www.secondsight.com.
Safe Harbor
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking statements." These statements may be identified by words such as "estimates," "anticipates," "projects," "plans," or "planned," "seeks," "may," "will," "expects," "intends," "believes," "should" and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Second Sight expects or anticipates will occur in the future are forward-looking statements. While management has based any forward looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report on Form 10-K as filed on March 17, 2015 and our other reports filed from time to time with the Securities and Exchange Commission. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160223005772/en/
Second Sight
Media
Pascale Communications, LLC
Allison Potter, 412-228-1678
Manager of Professional Relations
allison@pascalecommunications.com
or
Institutional Investors
In-Site Communications, Inc.
Lisa Wilson, 212-452-2793
President
lwilson@insitecony.com
or
Individual Investors
MZ North America
Greg Falesnik, 949-385-6449
Senior Vice President
greg.falesnik@mzgroup.us
Having my first burrito in several months...
Sold some $48.35
Come on $50
Understandable. I told myself I would unload the whole way up. Thousands of shares to get rid of so I do a few hundred or so at a time.
Unloaded a few more 40.60
NFLX is killing me. Things needs to get back over $100..
Took a few shares off the table at $40.00. I'll continue to slowly unload as this moves up in the mid $40's which is hopefully soon..
LMAO! I really have to laugh at this stuff at this point. Always perfectly timed when airlines start gaining upward momentum. It truly is unbelievable.
UAL is up 12 points in the past couple weeks vs AAL up under 5 points. Same for SAVE!
Hey just give me $40 so I can take some shares off..
JBLU has been red and is the biggest laggard.
I'm a seller of some shares over $40 which I thought I was going to get today. $37 might be the base for now.
$50 my selling point for a few shares. What a ride from mid $30's
Market looks amazing. Making all that money back.
Cheers
? That was over a year ago. What a moron...
No clue but I'll take it. Though my gut says sell some shares across the board...
Call me crazy but I feel like it's a sign to buy. All these bearish attacks...
Oh wow..
Oh and good call.
Careful.. Its a nice prop up ahead of Monday. Though no one knows what to expect Monday from china.
CORRECTING and REPLACING CyberArk Announces Record Fourth Quarter and Full Year 2015 Results
Source: Business Wire
Fourth quarter total revenue of $51 million increases 42% year-over-year
Full year total revenue of $161 million increases 56% year-over-year
In Business Outlook section under Full Year 2016, the second bullet should read: "Non-GAAP operating income is expected to be in the range of $39.7 million to $41.3 million." (instead of: Non-GAAP operating income is expected to be in the range of $49.7 million to $41.3 million).
The corrected release reads:
CYBERARK ANNOUNCES RECORD FOURTH QUARTER AND FULL YEAR 2015 RESULTS
Fourth quarter total revenue of $51 million increases 42% year-over-year
Full year total revenue of $161 million increases 56% year-over-year
CyberArk, (NASDAQ: CYBR), the company that protects organizations from cyber attacks that have made their way inside the network perimeter, today announced financial results for the fourth quarter and year ended December 31, 2015.
“2015 was another record year for CyberArk,” said Udi Mokady, CyberArk CEO. “We executed on our strategy to expand our sales and marketing reach, enhance our product offering, and strengthen our position as the recognized leader in Privileged Account Security. Our investments delivered record results across all financial and operational metrics. As we enter 2016, we believe that the momentum in our business positions us to capitalize on the rapidly growing, greenfield opportunity for this must-have new layer of enterprise security and to continue to deliver strong growth and solid profitability.”
Financial Highlights for the Fourth Quarter Ended December 31, 2015
Revenue:
Total revenue reached $51.5 million, up 42% compared with the fourth quarter of 2014.
License revenue was $33.0 million, up 35% compared with the fourth quarter of 2014.
Maintenance and Professional Services revenue was $18.4 million, up 55% compared with the fourth quarter of 2014.
Operating Income:
GAAP operating income was $10.9 million, an increase from $9.5 million in the fourth quarter of 2014. Non-GAAP operating income was $15.2 million, an increase from $10.1 million in the fourth quarter of 2014.
Net Income:
GAAP net income was $9.9 million, or $0.28 per diluted share, compared to GAAP net income of $6.7 million, or $0.19 per diluted share, in the fourth quarter of 2014. Non-GAAP net income was $13.8 million, or $0.39 per diluted share, compared to $7.2 million, or $0.21 per diluted share, in the fourth quarter of 2014.
Financial Highlights for the Full Year Ended December 31, 2015
Revenue:
Total revenue was $160.8 million, up 56% compared with 2014.
License revenue was $100.1 million, up 63% compared with 2014.
Maintenance and Professional Services revenue was $60.7 million, up 46% compared with 2014.
Operating Income:
GAAP operating income was $33.2 million, an increase from $20.5 million in 2014. Non-GAAP operating income was $43.6 million, an increase compared to $22.0 million in 2014.
Net Income:
GAAP net income was $25.8 million, or $0.73 per diluted share, an increase compared to GAAP net income of $10.0 million, or $0.34 per diluted share, in 2014. Non-GAAP net income was $35.3 million, or $1.00 per diluted share, an increase compared to $15.8 million, or $0.53 per diluted share, in 2014.
The tables at the end of this press release include a reconciliation of GAAP to non-GAAP operating income and net income for the three and twelve months ended December 31, 2015 and 2014. An explanation of these measures is also included below under the heading “Non-GAAP Financial measures.”
Balance Sheet and Cash Flow From Operations:
As of December 31, 2015, CyberArk had $238.3 million in cash and cash equivalents and short-term deposits. This compares with $249.7 million in cash and cash equivalents and short-term deposits as of September 30, 2015 and $177.2 million as of December 31, 2014.
During 2015, the Company generated $59.2 million in cash flow from operations, an increase compared to $23.2 million during in 2014.
Business Outlook
Based on information available as of February 11, 2016, CyberArk is issuing guidance for the first quarter and full year 2016 as indicated below.
First Quarter 2016:
Total revenue is expected to be in the range of $42.5 million to $43.5 million which represents 29% to 32% year-over-year growth.
Non-GAAP operating income is expected to be in the range of $6.9 million to $7.7 million.
Non-GAAP net income per share is expected to be in the range of $0.15 to $0.16. This assumes 35.9 million weighted average diluted shares.
Full Year 2016:
Total revenue is expected to be in the range of $205 million to $207 million which represents 27% to 29% year-over-year growth.
Non-GAAP operating income is expected to be in the range of $39.7 million to $41.3 million.
Non-GAAP net income per share is expected to be in the range of $0.83 to $0.86. This assumes 36.3 million weighted average diluted shares.
Conference Call Information
CyberArk will host a conference call today, at 4:30 p.m. Eastern Time (ET) to discuss the company’s fourth quarter and year end financial results and its business outlook. To access this call, dial +1 844-237-3590 (U.S.) or +1 484-747-6582 (international). The conference ID is 22614775. Additionally, a live webcast of the conference call will be available via the “Investor Relations” section of the company’s web site at www.cyberark.com. Following the conference call, a replay will be available for one week at +1 855-859-2056 (U.S.) or +1 404-537-3406 (international). The replay pass code is 22614775. An archived webcast of the conference call will also be available in the “Investor Relations” section of the company’s web site at www.cyberark.com.
About CyberArk
CyberArk (NASDAQ: CYBR) is the only security company focused on eliminating the most advanced cyber threats; those that use insider privileges to attack the heart of the enterprise. Dedicated to stopping attacks before they stop business, CyberArk proactively secures against cyber threats before attacks can escalate and do irreparable damage. The company is trusted by the world’s leading companies – including 40 percent of the Fortune 100 and 17 of the world’s top 20 banks – to protect their highest value information assets, infrastructure and applications. A global company, CyberArk is headquartered in Petach Tikvah, Israel, with U.S. headquarters located in Newton, MA. The company also has offices throughout EMEA and Asia-Pacific. To learn more about CyberArk, visit www.cyberark.com.
Copyright © 2016 CyberArk Software. All Rights Reserved. All other brand names, product names, or trademarks belong to their respective holders.
Non-GAAP Financial Measures
CyberArk believes that the use of non-GAAP operating income and non-GAAP net income is helpful to our investors. These financial measures are not measures of the Company’s financial performance under U.S. GAAP and should not be considered as alternatives to operating income or net income or any other performance measures derived in accordance with GAAP.
For the three months and year ended December 31, 2015, non-GAAP operating income is calculated as operating income excluding secondary offering related expenses, share-based compensation expense, amortization of intangible assets related to acquisitions, and acquisition related expenses. For the three months and year ended December 31, 2014, non-GAAP operating income is calculated as operating income excluding share-based compensation expense.
For the three months and year ended December 31, 2015, non-GAAP net income is calculated as net income excluding secondary offering related expenses, share-based compensation expense, amortization of intangible assets related to acquisitions, acquisition related expenses, and the tax effects related to the non-GAAP adjustments and for the three months and year ended December 31, 2014, non-GAAP net income is calculated as net income excluding share-based compensation expense and financial expenses resulting from the revaluation of warrants to purchase preferred shares.
Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company’s non-cash expense, the Company believes that providing non-GAAP financial measures that exclude share-based compensation, secondary offering related expenses, acquisition related expenses, and amortization of intangible assets related to acquisitions allows for more meaningful comparisons of its period to period operating results. Share-based compensation expense has been, and will continue to be for the foreseeable future, a significant recurring expense in the Company’s business and an important part of the compensation provided to its employees. In addition, the Company believes that excluding financial expenses with respect to revaluation of warrants to purchase preferred shares allows for more meaningful comparison between its net income from period to period, especially since upon the closing of the IPO, the warrants were exercised for ordinary shares, and as a result, are no longer evaluated at each balance sheet date. The Company believes that expenses related to its secondary offerings and acquisitions as well as amortization of intangible assets related to acquisitions do not reflect the performance of its core business and would impact period-to-period comparability.
Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in the Company’s industry, as other companies in the industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures as they exclude expenses that may have a material impact on the Company’s reported financial results. The presentation of non-GAAP financial information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with U.S. GAAP. CyberArk urges investors to review the reconciliation of its non-GAAP financial measures to the comparable U.S. GAAP financial measures included below, and not to rely on any single financial measures to evaluate its business.
Cautionary Language Concerning Forward-Looking Statements
This release may contain forward-looking statements, which express the current beliefs and expectations of CyberArk’s management. Such statements involve a number of known and unknown risks and uncertainties that could cause the Company’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: changes in the new and rapidly evolving cyber threat landscape; failure to effectively manage growth; fluctuations in quarterly results of operations; real or perceived shortcomings, defects or vulnerabilities in the Company’s solution or the failure of the solution to meet customers’ needs; the inability to acquire new customers or sell additional products and services to existing customers; competition from IT security vendors; our ability to successfully integrate Viewfinity, including by selling products to each other’s existing customers; and other factors discussed under the heading “Risk Factors” in the Company’s most recent annual report on Form 20-F filed with the Securities and Exchange Commission. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
CYBERARK SOFTWARE LTD.
Consolidated Statements of Operations
U.S. dollars in thousands (except per share data)
(Unaudited)
Three Months Ended Twelve Months Ended
December 31, December 31,
2014 2015 2014 2015
Revenues:
License $ 24,451 $ 33,037 $ 61,320 $ 100,113
Maintenance and professional services 11,854 18,429 41,679 60,699
Total revenues 36,305 51,466 102,999 160,812
Cost of revenues:
License 831 1,571 2,654 5,088
Maintenance and professional services 3,681 5,227 12,053 17,572
Total cost of revenues 4,512 6,798 14,707 22,660
Gross profit 31,793 44,668 88,292 138,152
Operating expenses:
Research and development 4,163 7,705 14,400 21,734
Sales and marketing 14,788 20,580 44,943 66,206
General and administrative 3,336 5,483 8,495 16,990
Total operating expenses 22,287 33,768 67,838 104,930
Operating income 9,506 10,900 20,454 33,222
Financial expenses, net (555 ) (233 ) (5,988 ) (1,479 )
Income before taxes on income 8,951 10,667 14,466 31,743
Taxes on income (2,291 ) (734 ) (4,512 ) (5,949 )
Net income $ 6,660 $ 9,933 $ 9,954 $ 25,794
Basic net income per ordinary share $ 0.22 $ 0.30 $ 0.46 $ 0.80
Diluted net income per ordinary share $ 0.19 $ 0.28 $ 0.34 $ 0.73
Shares used in computing net income
per ordinary shares, basic
30,466,847 33,243,103 13,335,059 32,124,772
Shares used in computing net income
per ordinary shares, diluted
34,673,940 35,727,077 29,704,730 35,322,716
Share-based Compensation Expense:
Three Months Ended Twelve Months Ended
December 31, December 31,
2014 2015 2014 2015
Cost of revenues $ 69 $ 213 $ 137 $ 499
Research and development 73 972 172 1,507
Sales and marketing 197 1,185 347 2,214
General and administrative 208 966 917 2,829
Total share-based compensation expense $ 547 $ 3,336 $ 1,573 $ 7,049
CYBERARK SOFTWARE LTD.
Consolidated Balance Sheets
U.S. dollars in thousands
(Unaudited)
December 31, December 31,
2014 2015
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 124,184 $ 234,539
Short-term bank deposits 52,997 3,713
Trade receivables 19,263 20,410
Prepaid expenses and other current assets 2,078 3,293
Total current assets 198,522 261,955
LONG-TERM ASSETS:
Property and equipment, net 2,148 3,584
Intangible assets, net - 18,558
Goodwill - 35,145
Severance pay fund 3,060 3,230
Prepaid expenses and other long-term assets 1,021 1,954
Long-term deferred tax asset 5,801 9,998
Total long-term assets 12,030 72,469
TOTAL ASSETS $ 210,552 $ 334,424
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Trade payables $ 1,835 $ 2,530
Employees and payroll accruals 10,322 15,860
Deferred revenues 22,594 37,104
Accrued expenses and other current liabilities 6,942 9,366
Total current liabilities 41,693 64,860
LONG-TERM LIABILITIES:
Deferred revenues 9,566 17,285
Other long-term liabilities 184 188
Accrued severance pay 4,101 4,667
Long-term deferred tax liabilities - 754
Total long-term liabilities 13,851 22,894
TOTAL LIABILITIES 55,544 87,754
SHAREHOLDERS' EQUITY:
Ordinary shares of NIS 0.01 par value 79 86
Additional paid-in capital 134,486 200,107
Accumulated other comprehensive loss (333 ) (93 )
Retained earnings 20,776 46,570
Total shareholders' equity 155,008 246,670
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 210,552 $ 334,424
CYBERARK SOFTWARE LTD.
Consolidated Statements of Cash Flows
U.S. dollars in thousands
(Unaudited)
Twelve Months Ended
December 31,
2014 2015
Cash flows from operating activities:
Net income $ 9,954 $ 25,794
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and Amortization 746 2,254
Share based compensation expenses 1,573 7,049
Tax benefit related to exercise of share options (645 ) (3,808 )
Deferred income taxes, net 45 (4,093 )
increase in trade receivables (6,535 ) (187 )
increase in prepaid expenses and other
current and long-term assets (159 ) (1,183 )
Increase (decrease) in trade payables (145 ) 322
Changes in fair value of warrants to purchase preferred
shares 4,309 -
Increase in short term and long term deferred revenues 7,682 21,254
Increase in employees and payroll accruals 3,501 5,011
Increase in accrued expenses and other
current and long-term liabilities 2,827 6,353
Increase in accrued severance pay, net 42 394
Net cash provided by operating activities 23,195 59,160
Cash flows from investing activities:
Proceeds from short and long term deposits 2,533 49,329
Investment in short and long term deposits (52,570 ) (619 )
Purchase of property and equipment (1,408 ) (2,066 )
Payments for business acquisitions, net of cash acquired - (53,656 )
Net cash used in investing activities (51,445 ) (7,012 )
Cash flows from financing activities:
Issuance of shares, net 88,468 52,575
Tax benefit related to exercise of share options 645 3,808
Proceeds from exercise of options and warrants 942 1,824
Net cash provided by financing activities 90,055 58,207
Increase in cash and cash equivalents 61,805 110,355
Cash and cash equivalents at the beginning of the period 62,379
124,184
Cash and cash equivalents at the end of the period $ 124,184 $ 234,539
CYBERARK SOFTWARE LTD.
Reconciliation of GAAP Measures to Non-GAAP Measures
U.S. dollars in thousands (except per share data)
(Unaudited)
Reconciliation of Operating Income to Non-GAAP Operating Income:
Three Months Ended Twelve Months Ended
December 31, December 31,
2014 2015 2014 2015
Operating income $ 9,506 $ 10,900 $ 20,454 $ 33,222
Secondary offering related expenses - - - 1,568
Share-based compensation 547 3,336 1,573 7,049
Amortization of intangible assets - Cost of revenues - 340 - 359
Amortization of intangible assets - Research and development - 478 - 749
Amortization of intangible assets - Sales and marketing
-
17
-
17
Acquisition related expenses - 160 - 677
Non-GAAP operating income $ 10,053 $ 15,231 $ 22,027 $ 43,641
Reconciliation of Net Income to Non-GAAP Net Income:
Three Months Ended Twelve Months Ended
December 31, December 31,
2014 2015 2014 2015
Net income $ 6,660 $ 9,933 $ 9,954 $ 25,794
Secondary offering related expenses - - - 1,568
Share-based compensation 547 3,336 1,573 7,049
Warrant adjustment - - 4,309 -
Amortization of intangible assets - Cost of revenues - 340 - 359
Amortization of intangible assets - Research and development
-
478 - 749
Amortization of intangible assets - Sales and marketing
-
17
-
17
Acquisition related expenses - 160 - 677
Taxes on income related to non-GAAP adjustments - (455 ) - (951 )
Non-GAAP net income $ 7,207 $ 13,809 $ 15,836 $ 35,262
Non-GAAP net income per share
Basic $ 0.24 $ 0.42 $ 0.90 $ 1.10
Diluted $ 0.21 $ 0.39 $ 0.53 $ 1.00
Weighted average number of shares
Basic 30,466,847 33,243,103 13,335,059 32,124,772
Diluted 34,673,940 35,727,077 29,704,730 35,322,716
View source version on businesswire.com: http://www.businesswire.com/news/home/20160211006402/en/
Investor Contact:
CyberArk
Erica Smith, 617-558-2132
ir@cyberark.com
or
Media Contact:
CyberArk
Christy Lynch, 617-796-3210
press@cyberark.com
374M volume omg
Sometimes I feel bad for retail getting suckered out of shares being forced to sell, only for the market to be manipulated back up. Bunch of crooks scamming and manipulating the markets up and down.
Anybody honestly believing OPEC is going to cut any kind of production is smoking drugs..